


Ask a doctor about a prescription for RELFYDESS 100 Units/mL Injectable Solution
Package Leaflet: Information for the User
Relfydess 100units/mL solution for injection
Botulinum toxin type A
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
Relfydess contains a substance, botulinum toxin type A, that causes muscles to relax. This medicine works by inhibiting nerve impulses in the muscles into which it is injected, preventing muscle contraction.
Relfydess is indicated for the temporary improvement of moderate to severe vertical lines between the eyebrows (glabellar lines) and lateral periorbital lines of moderate to severe severity (lateral canthal lines, also known as crow's feet). It is used in adults under 65 years of age, when these facial lines have a significant impact on the patient's well-being.
Do not useRelfydess:
Warnings and precautions
Consult your doctor before starting treatment with Relfydess:
This information will help your doctor make a decision about the risks and benefits of your treatment.
Special precautions
Very rarely, botulinum toxin can cause side effects far from the injection site (e.g., difficulty swallowing, coughing, and choking, difficulty speaking or breathing). These symptoms have been observed from hours to weeks after injection.
Seek medical attention immediately if you experience difficulty swallowing, speaking, or breathing.
The use of Relfydess may cause dry eyes. If you experience symptoms of dry eyes (such as eye irritation, sensitivity to light, or visual changes), consult your doctor.
Repeated treatments with botulinum toxin may result in muscle atrophy due to temporary paralysis of the treated muscles.
When botulinum toxin has been used at too frequent intervals or with excessive doses, it can lead to the formation of antibodies. The formation of neutralizing antibodies can reduce the effectiveness of treatment.
Children and adolescents
Relfydess is not recommended for use in persons under 18 years of age.
Other medicines and Relfydess
Tell your doctor if you are taking, have recently taken, or might take any other medicines. In particular, tell your doctor about the following medicines, as they may increase the effect of Relfydess:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before using this medicine.
Relfydess should not be used during pregnancy, or in women of childbearing potential who are not using contraceptive methods or are breastfeeding.
Driving and using machines
You may experience blurred vision or temporary muscle weakness after treatment with Relfydess. If this happens, do not drive or use machines.
Relfydess contains potassium, sodium, and polysorbate
This medicine contains potassium, less than 1 mmol of potassium (39 mg) per vial of 150 units; this is essentially "potassium-free".
This medicine contains less than 1 mmol of sodium (23 mg) per vial of 150 units; this is essentially "sodium-free".
This medicine contains 1.6 mg of polysorbate 80 per vial of 150 units, which is equivalent to 1.1 mg/mL. Polysorbates can cause allergic reactions. Tell your doctor if you have any allergies.
Relfydess should only be administered by doctors with the appropriate qualification and experience in this treatment and who have the appropriate equipment. Your doctor will inject Relfydess into the muscles intended for treatment.
The units of Relfydess are specific and are not interchangeable with other botulinum toxin preparations.
The recommended dose of Relfydess is:
The effect of the treatment usually occurs within a few days after injection and can last 6 months. The interval between Relfydess treatments will be decided by your doctor. The interval between two treatments should not be less than 3 months.
If you use more Relfydess than you should
Since the treatment is administered by a doctor with the appropriate qualification and experience, it is unlikely that you will be given too much medicine. However, if you receive more Relfydess than necessary, other muscles different from those treated may begin to weaken. Excessive doses can cause difficulty swallowing, speaking, and breathing problems. This may not happen immediately. If these symptoms appear, inform your doctor as soon as possible.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Normally, side effects occur within the first month after injection, are transient, and are mild to moderate.
Seek urgent medical attention if:
Tell your doctor if you experience any of the following side effects:
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Reporting of side effects:
If you experience any side effects, talk to your doctor, even if they are not listed in this leaflet. You can also report side effects directly via the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaRAM.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label. The expiry date is the last day of the month stated.
Store in a refrigerator (2°C – 8°C). Do not freeze. Keep the vials in the outer packaging to protect them from light.
Unopened vials can be stored at 25°C and protected from light. Relfydess (unopened vial) has demonstrated stability for up to 24 hours at room temperature.
Composition of Relfydess
Appearance and pack size
Relfydess is a clear, colorless to pale yellow solution for injection.
It comes in a single pack of 1 or 10 glass vials containing 1.5 mL of solution for injection.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Ipsen Pharma
70 rue Balard
75015 Paris
France
Manufacturer:
Q-Med AB
Seminariegatan 21
752 28 Uppsala
Sweden
You can request more information about this medicine from the local representative of the Marketing Authorization Holder:
Local representative:
Laboratorios Galderma SA
Serrano Galvache, 56.
28033 Madrid - Spain
Tel: 902 02 75 95
Date of last revision of this leaflet:July 2024
Other sources of information
Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/.
------------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
Dosage and administration:
Relfydess should only be administered by doctors with the appropriate qualification and experience in this treatment and who have the appropriate equipment, in accordance with national legislation and guidelines.
The units of Relfydess are specific and are not interchangeable with other botulinum toxin preparations.
Relfydess is prepared for use with a concentration of 10 units per 0.1 mL and does not require reconstitution.
Each vial is intended for a single patient in a single treatment session. Any residual product should be discarded.
Table 1:Relfydess dosing instructions
Indication(s) | Recommended total dose | Dose per injection |
Glabellar lines (GL) | 50 units (0.5 mL) | 5 injections of 10 units (0.1 mL): 2 injections on each side of the corrugator muscle and 1 injection in the procerus muscle near the nasofrontal angle |
Lateral canthal lines (LCL) | 60 units (0.6 mL) | 6 injections of 10 units (0.1 mL): 3 injections on each side of the face in the orbicularis oculi muscle |
Combined treatment of glabellar lines and lateral canthal lines | 110 units (1.1 mL) | 11 total injections of 10 units (0.1 mL) for combined treatment of GL and LCL |
The dosing and treatment interval depend on the individual response of each patient, but should not exceed the maximum allowed doses or the minimum interval of 12 weeks.
The name and batch number of the product administered should be clearly recorded to ensure the traceability of biological medicines.
Special precautions for disposal and other handling
Instructions for use, handling, and disposal should be strictly followed.
RECOMMENDATIONS FOR THE DISPOSAL OF CONTAMINATED MATERIALS
Immediatelyafter treatment and before disposal, any remaining Relfydess (in the vial or syringe) should be inactivated with a diluted solution of sodium hypochlorite (0.1% NaClO) or sodium hydroxide solution (1% NaOH). Used vials, syringes, and materials should not be emptied and should be disposed of in accordance with local requirements.
RECOMMENDATIONS IN CASE OF ACCIDENT DURING HANDLING OF BOTULINUM TOXIN
These instructions for use, handling, and disposal should be strictly followed.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for RELFYDESS 100 Units/mL Injectable Solution – subject to medical assessment and local rules.